CHMP recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone)
Shire announces the CHMP of the EMA has adopted a positive opinion recommending the granting of Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), a recombinant human protein, as an adjunctive treatment for adult patients with chronic hypoparathyroidism. February 24, 2017